{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:50:16Z","timestamp":1788385816876,"version":"build-2803163510"},"reference-count":69,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T00:00:00Z","timestamp":1629849600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["K23-NS11416-01A1"],"award-info":[{"award-number":["K23-NS11416-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1 NS115139"],"award-info":[{"award-number":["RO1 NS115139"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["U19 AG062418"],"award-info":[{"award-number":["U19 AG062418"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["P30 AG010124"],"award-info":[{"award-number":["P30 AG010124"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["RO1 NS082265"],"award-info":[{"award-number":["RO1 NS082265"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JPM"],"abstract":"<jats:p>Concomitant neuropathological hallmarks of Alzheimer\u2019s Disease (AD) are common in the brains of people with Parkinson\u2019s disease (PD). Furthermore, AD biomarkers are associated with cognitive decline and dementia in PD patients during life. Here, we highlight the considerable overlap between AD and PD, emphasizing neuropathological, biomarker, and mechanistic studies. We suggest that precision medicine approaches may successfully identify PD patients most likely to develop concomitant AD. The ability to identify PD patients at high risk for future concomitant AD in turn provides an ideal cohort for trials of AD-directed therapies in PD patients, aimed at delaying or preventing cognitive symptoms.<\/jats:p>","DOI":"10.3390\/jpm11090834","type":"journal-article","created":{"date-parts":[[2021,8,26]],"date-time":"2021-08-26T00:19:26Z","timestamp":1629937166000},"page":"834","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Are Parkinson\u2019s Disease Patients the Ideal Preclinical Population for Alzheimer\u2019s Disease Therapeutics?"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-1496","authenticated-orcid":false,"given":"Thomas F.","family":"Tropea","sequence":"first","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Chen-Plotkin","sequence":"additional","affiliation":[{"name":"Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,8,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00019052-199408000-00011","article-title":"Epidemiology of Movement-Disorders","volume":"7","author":"Tanner","year":"1994","journal-title":"Curr. Opin. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJM2003ra020003","article-title":"Alzheimer\u2019s Disease and Parkinson\u2019s Disease","volume":"348","author":"Nussbaum","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1474-4422(06)70471-9","article-title":"Epidemiology of Parkinson\u2019s disease","volume":"5","author":"Breteler","year":"2006","journal-title":"Lancet Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1212\/01.wnl.0000247740.47667.03","article-title":"Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030","volume":"68","author":"Dorsey","year":"2007","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Marras, C., Beck, J.C., Bower, J.H., Roberts, E., Ritz, B., Ross, G.W., Abbott, R.D., Savica, R., Van Den Eeden, S.K., and Willis, A.W. (2018). Prevalence of Parkinson\u2019s disease across North America. NPJ Park. Dis., 4.","DOI":"10.1038\/s41531-018-0058-0"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1002\/mds.26424","article-title":"MDS clinical diagnostic criteria for Parkinson\u2019s disease","volume":"30","author":"Postuma","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/mds.23462","article-title":"The impact of non-motor symptoms on health-related quality of life of patients with Parkinson\u2019s disease","volume":"26","author":"Kurtis","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/gps.3970","article-title":"Quality of life, health status and caregiver burden in Parkinson\u2019s disease: Relationship to executive functioning","volume":"29","author":"Kudlicka","year":"2014","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1002\/mds.23661","article-title":"The economic impact of cognitive impairment in Parkinson\u2019s disease","volume":"26","author":"Vossius","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1212\/WNL.56.6.730","article-title":"Risk of dementia in Parkinson\u2019s disease: A community-based, prospective study","volume":"56","author":"Aarsland","year":"2001","journal-title":"Neurology"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/mds.21956","article-title":"The Sydney Multicenter Study of Parkinson\u2019s disease: The inevitability of dementia at 20 years","volume":"23","author":"Hely","year":"2008","journal-title":"Mov. Disord."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1002\/mds.23823","article-title":"MDS task force on mild cognitive impairment in Parkinson\u2019s disease: Critical review of PD-MCI","volume":"26","author":"Litvan","year":"2011","journal-title":"Mov. Disord."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/nan.12311","article-title":"Synucleinopathies: Past, present and future","volume":"42","author":"Spillantini","year":"2016","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1093\/brain\/awy146","article-title":"Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated","volume":"141","author":"Robinson","year":"2018","journal-title":"Brain"},{"key":"ref_15","first-page":"1234","article-title":"Neuropathology of dementia in patients with Parkinson\u2019s disease: A systematic review of autopsy studies","volume":"90","author":"Smith","year":"2019","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_16","unstructured":"Alzheimer\u2019s Disease International (2018). World Alzheimer Report 2018\u2014The State of the Art of Dementia Research: New Frontiers, Alzheimer\u2019s Disease International."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jalz.2011.03.003","article-title":"Toward defining the preclinical stages of Alzheimer\u2019s disease: Recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"(2021). 2021 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s Dement., 17, 327\u2013406.","DOI":"10.1002\/alz.12328"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00401-011-0910-3","article-title":"National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease: A practical approach NIH Public Access","volume":"123","author":"Montine","year":"2012","journal-title":"Acta Neuropathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.jalz.2015.05.003","article-title":"The Alzheimer\u2019s Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans","volume":"11","author":"Kang","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer\u2019s disease spectrum patients: A randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers. Res. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1002\/gps.2723","article-title":"ADAPT Research Team Effects of non-steroidal anti-inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: Findings from the randomized controlled Alzheimer\u2019s Disease Anti-inflammatory Prevention Trial","volume":"27","author":"Leoutsakos","year":"2012","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"ref_23","unstructured":"(2021, June 15). A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants with Prodromal to Mild Alzheimer\u2019s Disease (AD) (CREAD 2), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02670083."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.trci.2018.02.002","article-title":"The Alzheimer\u2019s Prevention Initiative Autosomal-Dominant Alzheimer\u2019s Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer\u2019s disease, including a placebo-treated noncarrier cohort","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_25","unstructured":"(2021, June 15). Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer\u2019s Disease Caused by a Genetic Mutation, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01760005."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3233\/JAD-2008-13209","article-title":"Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer\u2019s disease","volume":"13","author":"Carlsson","year":"2008","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nature19323","article-title":"The antibody aducanumab reduces A\u03b2 plaques in Alzheimer\u2019s disease","volume":"537","author":"Sevigny","year":"2016","journal-title":"Nature"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s13195-018-0415-6","article-title":"Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer\u2019s disease: Randomized, double-blind, placebo-controlled study","volume":"10","author":"Timmers","year":"2018","journal-title":"Alzheimers. Res. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","article-title":"Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer\u2019s disease","volume":"11","author":"Wunderlich","year":"2019","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease","volume":"7","author":"Lowe","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"P1623","DOI":"10.1016\/j.jalz.2018.07.213","article-title":"P4-389: Elenbecestat, E2609, a bace inhibitor: Results from a phase-2 study in subjects with mild cognitive impairment and mild-to-moderate dementia due to alzheimer\u2019s disease","volume":"14","author":"Lynch","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer\u2019s disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alzheimer\u2019s Res. Ther."},{"key":"ref_33","unstructured":"(2021, June 15). A Study of JNJ-63733657 in Participants With Early Alzheimer\u2019s Disease\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04619420?term=JNJ-63733657&draw=2&rank=1."},{"key":"ref_34","unstructured":"(2021, June 15). SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer\u2019s Disease (AD) (SIGNAL-AD), Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04381468."},{"key":"ref_35","unstructured":"(2021, June 15). PRESS RELEASE AC Immune Reports Top Line Results from TAURIEL Phase 2 Trial Evaluating Semorinemab in Early Alzheimer\u2019s Disease. Available online: https:\/\/ir.acimmune.com\/static-files\/7296e650-85ea-4151-aca5-6f63ec71653c."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/WAD.0b013e3181d61fea","article-title":"Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers","volume":"24","author":"Vega","year":"2010","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"ref_37","unstructured":"(2021, June 15). Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008357?term=solanezumab&draw=2&rank=5."},{"key":"ref_38","unstructured":"(2021, June 15). A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer\u2019s Disease\u2014Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02760602?term=solanezumab&draw=2&rank=1."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1812840","article-title":"Randomized Trial of Verubecestat for Prodromal Alzheimer\u2019s Disease","volume":"380","author":"Egan","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1002\/ana.25392","article-title":"Cognitive and Pathological Influences of Tau Pathology in Lewy Body Disorders","volume":"85","author":"Coughlin","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1097\/NEN.0000000000000018","article-title":"Confluence of \u03b1-Synuclein, Tau, and \u03b2-Amyloid Pathologies in Dementia With Lewy Bodies","volume":"72","author":"Gelpi","year":"2013","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00401-020-02199-7","article-title":"ADNC-RS, a clinical-genetic risk score, predicts Alzheimer\u2019s pathology in autopsy-confirmed Parkinson\u2019s disease and Dementia with Lewy bodies","volume":"140","author":"Dai","year":"2020","journal-title":"Acta Neuropathol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"229","DOI":"10.3233\/JAD-180390","article-title":"Brain Amyloid Contribution to Cognitive Dysfunction in Early-Stage Parkinson\u2019s Disease: The PPMI Dataset","volume":"66","author":"Fiorenzato","year":"2018","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1001\/jamaneurol.2018.0629","article-title":"Prevalence and outcomes of amyloid positivity among persons without dementia in a longitudinal, population-based setting","volume":"75","author":"Roberts","year":"2018","journal-title":"JAMA Neurol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.26191","article-title":"Amyloid deposition in Parkinson\u2019s disease and cognitive impairment: A systematic review","volume":"30","author":"Petrou","year":"2015","journal-title":"Mov. Disord."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1474-4422(16)30291-5","article-title":"Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: A retrospective analysis","volume":"16","author":"Irwin","year":"2017","journal-title":"Lancet Neurol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1136\/jnnp-2016-313775","article-title":"Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies","volume":"88","author":"Lemstra","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1212\/WNL.0000000000011699","article-title":"Cognitive Profile and Markers of Alzheimer Disease-Type Pathology in Patients With Lewy Body Dementias","volume":"96","author":"Howard","year":"2021","journal-title":"Neurology"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.parkreldis.2016.07.008","article-title":"Phenotypic differences based on staging of Alzheimer\u2019s neuropathology in autopsy-confirmed dementia with Lewy bodies","volume":"31","author":"Peavy","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jalz.2014.11.001","article-title":"2014 Update of the Alzheimer\u2019s Disease Neuroimaging Initiative: A review of papers published since its inception","volume":"11","author":"Weiner","year":"2015","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","article-title":"CSF biomarkers predict a more malignant outcome in Alzheimer disease","volume":"74","author":"Wallin","year":"2010","journal-title":"Neurology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaneurol.2015.3037","article-title":"Association of cerebrospinal fluid neurofilament light concentration with Alzheimer disease progression","volume":"73","author":"Zetterberg","year":"2016","journal-title":"JAMA Neurol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jamaneurol.2018.3746","article-title":"Association of Cerebrospinal Fluid Neurofilament Light Protein Levels with Cognition in Patients with Dementia, Motor Neuron Disease, and Movement Disorders","volume":"76","author":"Olsson","year":"2019","journal-title":"JAMA Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1212\/01.WNL.0000046581.81650.D0","article-title":"CSF A\u00df 42 levels correlate with amyloid-neuropathology in a population-based autopsy study","volume":"60","author":"Strozyk","year":"2003","journal-title":"Neurology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","article-title":"CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: A systematic review and meta-analysis","volume":"15","author":"Olsson","year":"2016","journal-title":"Lancet Neurol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"228fs13","DOI":"10.1126\/scitranslmed.3007941","article-title":"The A4 study: Stopping AD before symptoms begin?","volume":"6","author":"Sperling","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1212\/WNL.0b013e3181f39a78","article-title":"CSF amyloid \u03b2 1-42 predicts cognitive decline in Parkinson disease","volume":"75","author":"Siderowf","year":"2010","journal-title":"Neurology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1007\/s12031-015-0647-x","article-title":"CSF \u03b2-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease","volume":"58","author":"Terrelonge","year":"2016","journal-title":"J. Mol. Neurosci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/mds.26578","article-title":"L ongitudinal M easurements of C erebrospinal F luid B iomarkers in P arkinson\u2019s D isease","volume":"31","author":"Hall","year":"2016","journal-title":"Mov. Disord."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e1104","DOI":"10.1212\/WNL.0000000000008088","article-title":"Blood NfL: A biomarker for disease severity and progression in Parkinson disease","volume":"93","author":"Lin","year":"2019","journal-title":"Neurology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/mds.27204","article-title":"APOE, thought disorder, and SPARE-AD predict cognitive decline in established Parkinson\u2019s disease","volume":"33","author":"Tropea","year":"2018","journal-title":"Mov. Disord."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2713","DOI":"10.1007\/s00415-020-09757-9","article-title":"Predictors of cognitive impairment in Parkinson\u2019s disease: A systematic review and meta-analysis of prospective cohort studies","volume":"268","author":"Guo","year":"2021","journal-title":"J. Neurol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/1750-1326-9-43","article-title":"Alpha-synuclein and tau: Teammates in neurodegeneration?","volume":"9","author":"Moussaud","year":"2014","journal-title":"Mol. Neurodegener."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.semcdb.2018.05.005","article-title":"The interaction of \u03b1-synuclein and Tau: A molecular conspiracy in neurodegeneration?","volume":"99","author":"Yan","year":"2020","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"25481","DOI":"10.1074\/jbc.274.36.25481","article-title":"alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356","volume":"274","author":"Jensen","year":"1999","journal-title":"J. Biol. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1126\/science.1082324","article-title":"Initiation and synergistic fibrillization of tau and alpha-synuctein","volume":"300","author":"Giasson","year":"2003","journal-title":"Science"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1038\/nm.3457","article-title":"Cell-to-cell transmission of pathogenic proteins in neurodegenerative diseases","volume":"20","author":"Guo","year":"2014","journal-title":"Nat. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e20192193","DOI":"10.1084\/jem.20192193","article-title":"\u03b1-Synuclein modulates tau spreading in mouse brains","volume":"218","author":"Bassil","year":"2021","journal-title":"J. Exp. Med."}],"container-title":["Journal of Personalized Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/9\/834\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T06:51:17Z","timestamp":1760165477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4426\/11\/9\/834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,25]]},"references-count":69,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,9]]}},"alternative-id":["jpm11090834"],"URL":"https:\/\/doi.org\/10.3390\/jpm11090834","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints202107.0116.v1","asserted-by":"object"}]},"ISSN":["2075-4426"],"issn-type":[{"value":"2075-4426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,25]]}}}